Biotechnology
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe
2025, one of the industry's premier gatherings for innovation in protein and
antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein
2025-11-19 22:17
842
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...
2025-11-19 20:08
584
Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care
JERUSALEM, Nov. 19, 2025 /PRNewswire/ -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by theBiomedical Advanced Research and Developmen...
2025-11-19 13:01
402
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxali...
2025-11-19 05:15
1902
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a subst...
2025-11-17 22:15
846
AKA Foods Secures 17.2 Million Dollars in Seed Funding to launch the world's first secure AI system for food innovation
New AKA Studio consolidates organisational knowledge, incorporates sensory
evaluation, and applies AI assistants to guide formulation and optimisation
AMSTELVEEN, Netherlands, Nov. 17, 2025 /PRNewswire/ -- AKA Foods Ltd
2025-11-17 17:00
685
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka; President and COO:Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirm...
2025-11-14 16:00
810
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blo...
2025-11-13 21:00
827
Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...
2025-11-11 22:00
1057
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...
2025-11-11 22:00
999
MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...
2025-11-11 17:40
978
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...
2025-11-10 20:30
942
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences
2025-11-10 20:00
805
Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech
BEIJING, Nov. 10, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. ("Shunfeng BioTech") for the Cas...
2025-11-10 20:00
837
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...
2025-11-10 19:39
794
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...
2025-11-08 18:00
1261
Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precis...
2025-11-07 22:05
1643
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a ...
2025-11-07 22:00
2380
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...
2025-11-07 20:00
1138
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...
2025-11-07 14:00
1368
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 314 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 292 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 289 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 286 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2765
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2310
